2018

Data from a large observational study comprising 17,312 patients admitted at the Acute Medical Unit at Copenhagen University Hospital Amager and Hvidovre, Denmark has been published in the highly accredited medical journal Critical Care Medicine.

Results show that combining the National Early Warning Score (NEWS) with suPAR improves risk stratification significantly in acute medical patients.

Meet us at 4th Panhellenic Congress of Resuscitation and Emergency Care on October 5-6 in Athens, Greece, and participate in our suPAR Satellite Symposium!

Data from the TRIAGE III study were presented at the 12th European Congress of Emergency Medicine in Glasgow, and shows that use of suPARnostic® Quick Triage shortened patients’ stay at Emergency Departments by 6.5 hours and allowed a significantly higher proportion of patients to be discharged within 24 hours.

Meet us at XII International Conference on Nephrology, Renal Replacement Therapy and Kidney Transplantation on September 13-14 in Minsk, Belarus, and hear the suPAR presentation.

Meet us at EuSEM 2018, the 12th European Congress on Emergency Medicine, on September 8-12 in Glasgow, Scotland and hear the suPAR presentations.

ViroGates has completed the development and regulatory approval of its first suPARnostic® TurbiLatex product, based on the turbidimetric technology.

The 9th City Clinical Hospital Minsk, Belarus has entered an agreement with ViroGates for the use of suPARnostic® Quick Triage in clinical routine practice for the detection and severity assessment of Chronic Kidney Disease (CKD) and sepsis patients.

Our lists of Key suPAR Publications and links to PubMed have been updated.

Meet us at The Interdisciplinary Congress of Emergency Medicine on July 5-7 in Cluj-Napoca, Romania and hear about suPARnostic® !

ViroGates’ initial public offering of new shares was 141% oversubscribed.
As of June 26, 2018 ViroGates is listed on Nasdaq OMX First North in Denmark.

ViroGates publishes prospectus for its initial public offering in Copenhagen.

ViroGates intends to strengthen its capital structure to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage.

Meet us at SEMES Emergency Conference in Toledo, Spain on June 6-8 and hear about suPARnostic®!

 

ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.

Meet us at XI Congresso Nazionale SIMEU - the national Emergeny Congress of Italy - on May 24-26 in Rome, Italy.

Meet us at DASEM 2018 - Årsmøde Dansk Selskab for Akutmedicin / Danish Society for Emergency Medicine on April 20-21 in Horsens, Denmark.

Please welcome Thomas Krarup who has joined ViroGates as new VP Sales & Marketing.

Thomas' educational background includes a PhD in biology from Copenhagen University, Denmark, and Syracuse University, USA.

Kidney Disease and The Heart: Is suPAR the Missing Link?

Sunday, March 11, 10:45 a.m. – 12:15 p.m.
Presented by Salim Hayek, MD

Meet us at at Emergency Conference Aute Cardiovascular Care 2018, March 3-5 and hear about suPARnostic®

We welcome Alura med. as new distributor of suPARnostic® in Serbia!

Meet us at the following conferences in 2018, where we plan to participate:

Our lists of Key suPAR Publications and links to PubMed have been updated.